Evidence map›Paper›PMID 22575025›Full record

Trial reportJournal of cutaneous pathology2012

CD147 expression in advanced cutaneous squamous cell carcinoma.

Larissa Sweeny, Nichole R Dean, John W Frederick, J Scott Magnuson, William R Carroll, Renee A Desmond, Eben L Rosenthal

Open access · greenAbstract readClinical Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of cutaneous pathology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
0.8field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Article
  5. Review
  6. Oh, the Mutations You'll Acquire! A Systematic Overview of Cutaneous Squamous Cell Carcinoma.Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology · 2021
    Review
  7. Review
  8. Article
  9. Monocarboxylate transporters in cancer.Molecular metabolism · 2020
    Review
  10. Article
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Larissa SweenyDivision of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of Alabama at Birmingham, AL 35233, USA.
Nichole R Dean
John W Frederick
J Scott Magnuson
William R Carroll
Renee A Desmond
Eben L Rosenthal
University of Alabama at Birmingham · US

Funding

Research Training Program in Surgical OncologyT32CA091078 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI KENNEDY, GREGORY DEAN · 2002 to 2017
$4.8M
CD147 as a Novel Target in Head and Neck CancerR01CA142637 · NCI · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI ROSENTHAL, EBEN L. · 2010 to 2014
$1.3M
NCI NIH HHS 2T32 CA091078-06NCI NIH HHS R01 CA142637NCI NIH HHS R01CA142637-01NCI NIH HHS T32 CA091078
6 · The paper itself

Abstract

backgroundCD147 is upregulated in multiple cancer types, but its expression in advanced cutaneous squamous cell carcinoma (SCC) is unknown. Our purpose was to evaluate the expression patterns of CD147 and related monocarboxylate transporters (MCT1, MCT4) to determine their correlation with survival.

methodsThis is a retrospective cohort study of patients with advanced stage cutaneous SCC of the head and neck who presented to a tertiary care center between 1998 and 2006 (n=50). CD147, MCT1 and MCT4 expression levels were assessed using immunofluorescence analysis of archived tumor samples and correlated with survival and clinicopathologic characteristics.

resultsThe majority of patients (92%, n = 46) were diagnosed with stage III disease, with 46% (n = 23) having positive regional lymph node metastasis and 8% (n = 4) with distant metastasis. Primary malignancies had an overexpression of CD147 (78%; n = 35), MCT1 (23%; n = 10) and MCT4 (47%; n = 20). In addition, there was a significant relationship between the overexpression of CD147 and node positive disease (p = 0.048). Two- and five-year survival rates were 69 and 61%, respectively. There was a trend toward decreased survival in patients with overexpression of CD147 (p = 0.17), MCT1 (p = 0.11) and MCT4 (p = 0.15).

conclusionCD147 may represent a biomarker or potential therapeutic target in advanced cutaneous SCC.

Indexed as

Gene Expression Regulation, NeoplasticAdultAgedAged, 80 and overBasiginBiomarkers, TumorCarcinoma, Squamous CellDisease-Free SurvivalFemaleHead and Neck NeoplasmsHumansMaleMiddle AgedMonocarboxylate Transport Protein 1Monocarboxylic Acid TransportersMuscle ProteinsBasiginBiomarkers, TumorBSG protein, humanMonocarboxylate Transport Protein 1Monocarboxylic Acid TransportersMuscle ProteinsNeoplasm ProteinsSLC16A4 protein, humanSymporters

Identifiers

PMID22575025
PMCPMC3634338
OpenAlexW2011493192

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.